K. Cuppens
18 Papers
1 Citations
K. Cuppens is an academic researcher. The author has contributed to research in topics: Medicine & Lung cancer. The author has an hindex of 2, co-authored 10 publications.
Chat about Author
Papers
Bintrafusp alfa versus pembrolizumab in patients with treatment-naive, PD-L1-high advanced non-small cell lung cancer: a randomized, open-label, phase 3 trial.
Byoung Chul Cho,Jong-Seok Lee,Yi-Long Wu,Irfan Cicin,Manuel Cobo Dols,Myung-Ju Ahn,K. Cuppens,Remi Veillon,Ernest Nadal,Josiane Mourão Dias,Claudio Martin,Martin Reck,Edward B. Garon,Enriqueta Felip,Luis Paz-Ares,Françoise Mornex,Everett E. Vokes,Alex A. Adjei,Clifford G. Robinson,Masashi Sato,Yulia Vugmeyster,Andreas Machl,Francois Audhuy,S. Chaudhary,Fabrice Barlesi +24 more
TL;DR: First-line treatment with bintrafusp alfa did not demonstrate superior efficacy compared with pembrolizumab in patients with PD-L1-high, advanced NSCLC.
32
Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer: a randomized phase 2 trial.
Martin Schuler,K. Cuppens,Till Plönes,Marcel Wiesweg,Bert Du Pont,Balazs Hegedus,Johannes Köster,Fabian Mairinger,Kaid Darwiche,A. Paschen,Brigitte Maes,Michel Vanbockrijck,David Lähnemann,Fang Zhao,Hubertus Hautzel,Dirk Theegarten,K. Hartemink,Henning Reis,Paul Baas,Alexander Schramm,Clemens Aigner +20 more
TL;DR: A phase 2 trial of neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer achieved high curative resection rates (95%) and favorable survival rates (89-100%) with manageable toxicity, establishing dual PD-1 and LAG-3 targeting as a safe and effective approach.
20
HLA-I diversity and tumor mutational burden by comprehensive next-generation sequencing as predictive biomarkers for the treatment of non-small cell lung cancer with PD-(L)1 inhibitors.
K. Cuppens,Paul Baas,Ellen Geerdens,Bert Cruys,Guy Froyen,L. Decoster,Michiel Thomeer,Brigitte Maes +7 more
TL;DR: The predictive utility of human leukocyte antigen class I (HLA-I) diversity and tumor mutational burden (TMB) by comprehensive next-generation sequencing was reported in this article .
17
Liquid Biopsy in Early-Stage Lung Cancer: Current and Future Clinical Applications
TL;DR: The use of liquid biopsies to enhance diagnosis, optimize perioperative systemic treatments, and allow early detection of relapse is a possible strategy to reduce the burden of lung cancer as mentioned in this paper .
Surgical outcomes of patients with resectable non-small-cell lung cancer receiving neoadjuvant immunotherapy with nivolumab plus relatlimab or nivolumab: Findings from the prospective, randomized, multicentric phase II study NEOpredict-Lung.
Clemens Aigner,Bert Du Pont,Koen J. Hartemink,Marcel Wiesweg,M Vanbockrijck,Kaid Darwiche,Balazs Hegedus,Alexander Schramm,Hubertus Hautzel,Brigitte Maes,Dirk Theegarten,Hans-Ulrich Schildhaus,Paul Baas,K. Cuppens,Martin Schuler,Till Plönes +15 more
TL;DR: In this paper , the feasibility of surgical resection for non-small-cell lung cancer (NSCLC) after preoperative immune checkpoint inhibitor therapy (PICIT) with PD-1/PD-L1 and CTLA-4 inhibitors was established.
9